Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
The Center for Value-Based Insurance Design (V-BID) highlighted an article from The American Journal of Managed Care® (AJMC®) in its 2017 fall update. The article, “VBID Summit Explores How Congress Can Make High-Deductible Plans Work for Consumers,” reported on the healthcare concept of VBID, which seeks to remove financial barriers for high-value care. The idea has been pioneered by the co-editors-in-chief of AJMC®, A. Mark Frederick, MD, of the University of Michigan and its V-BID Center, and Michael E. Chernew, PhD, of Harvard Medical School.
The National Pharmaceutical Council’s Daily Newsfeed e-mail on Friday highlighted an article published by AJMC®. The article, "ICER Reviews $13.9 Million Grant, Plans to Assess All New Drugs,” reported on The Institute for Clinical and Economic Review’s (ICER) announcement that they received a 3-year grant from the Laura and John Arnold Foundation (LJAF). ICER, a non-profit drug-pricing watchdog, plans to use the funds in support of its ongoing efforts to change the ways in which new prescription drugs are evaluated and priced.
A study published in AJMC® was mentioned on Advance Cardio Health’s Facebook page. The study, “Few Patients Prescribed PCSK9 Inhibitors Actually Receive the Therapy,” found that many patients who are prescribed PCSK9 inhibitors often face challenges involving patient access, including low approval rates during the first year of availability.
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
FDA Expands Access to Approved CAR T-Cell Therapies by Eliminating REMS
June 30th 2025The FDA has removed Risk Evaluation and Mitigation Strategies (REMS) for approved chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies, aiming to ease provider burden and expand patient access.
Read More